Glaukos (Laguna Hills, CA) a clinical-stage ophthalmology medical device company focused on the management of open-angle glaucoma, closed a $29.5M Series E. Participants include OrbiMed, Frazier Healthcare Ventures, InterWest Partners, Domain Associates and Versant Ventures.

VisionCare Ophthalmic Technologies (Saratoga, CA) a commercial-stage medical device company focused on advanced age-related macular degeneration, closed a $31M Series E financing. Participants include Saints Venture Capital, Giza Ventures, Generali Financial Holdings, BSI, Pitango Venture Capital, Three Arch Partners, Onset Ventures and Infinity CSVC Management.

NanoInk (Skokie, IL) a commercial-stage a protein analysis, biomaterial manufacturing and biodiscovery assay kit developer, closed a$65M Series E financing. Participants include Lurie Investment Fund.

Accuri Cytometers (Ann Arbor, MI) a commercial-stage device company focused on flow cytometery solutions for the R&D market, closed a $6M Series E financing. Participants include Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and InvestMichigan.

Complete Genomics (Mountain View, CA) a commercial-stage sequencing company building a human genome sequencing center to enable academic and biopharma researchers to conduct large-scale human genome studies, closed a $39M Series E financing. Participants include Sands Capital Management, Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners.

Gemin X Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company focused on chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $8M Series E financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.

Cyntellect (San Diego, CA) a commercial-stage medical device company focused on in situ, microplate-based cytometry cell analysis, closed a $9M Series E, bringing the total round to $16M. Participants were not disclosed.

Nereus Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on non-small cell lung cancer and myeloma, closed a $20M Series E financing. Participants include HBM BioVentures, Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund and Astellas Venture Management.

Anulex Technologies (Minnetonka, MN) a commercial-stage medical device company focused on herniated discectomy procedures, closed a $18.3M Series E financing. Participants include Hatteras Late Stage VC Fund, Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]

Anitsense Pharma (Germany) a clinical-stage biopharmaceutical company focused on antisense gene silencing for pancreatic cancer, malignant melanoma and colorectal cancer, closed a $17.5M Series E financing. Participants include MIG Fonds and Global Asset Fund.

TransMedics (Andover, MA) a clinical-stage medical device company focused on a technology platform to maintain donor organs in near-physiologic and functioning condition during transport for organ transplantation, closed a $36M Series E financing. Participants include Foundation Capital, Kleiner Perkins Caufield & Byers, Flagship Ventures, 3i Group, Tudor Investment, VantagePoint Venture Partners, Sherbrooke Partners, Alta Partners, [...]

ImpactRx (Mt. Laurel, NJ) a commercial-stage provider of online content measuring the impact of pharmaceutical promotion on the prescribing behavior of the nation’s highest value physicians, closed a $1.2M Series E financing. Participants have included Mediphase Venture Partners, 3i Group, Oxford Bioscience Partners and Merck.